Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 20/20 | 0.76 |
| ▸ | PIK3CG | P48736 | 18/20 | 0.76 |
| ▸ | PIK3CB | P42338 | 17/20 | 0.76 |
| ▸ | PIK3CA | P42336 | 16/20 | 0.76 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4087846 | 1.00 | PIK3CD (0.76) | PIK3CDPIK3CGPIK3CBPIK3CACYP2D6 | |
| SCHEMBL2718892 | 1.00 | PIK3CD (0.76) | PIK3CDPIK3CGPIK3CBPIK3CACYP2D6 | |
| SCHEMBL10198872 | 0.93 | PIK3CD (0.68) | PIK3CDPIK3CGPIK3CBPIK3CACYP2D6 | |
| SCHEMBL10198868 | 0.93 | PIK3CD (0.68) | PIK3CDPIK3CGPIK3CBPIK3CACYP2D6 | |
| SCHEMBL2719868 | 0.93 | PIK3CD (0.68) | PIK3CDPIK3CGPIK3CBPIK3CACYP2D6 | |
| SCHEMBL2717767 | 0.90 | PIK3CD (0.62) | PIK3CDPIK3CGPIK3CBPIK3CAPIK3R1 | |
| SCHEMBL2717612 | 0.89 | PIK3CD (0.61) | PIK3CDPIK3CGPIK3CBPIK3CA | |
| SCHEMBL15437004 | 0.89 | PIK3CD (0.61) | PIK3CDPIK3CGPIK3CBPIK3CA | |
| SCHEMBL15437078 | 0.89 | PIK3CD (0.61) | PIK3CDPIK3CGPIK3CBPIK3CA | |
| SCHEMBL15437120 | 0.89 | PIK3CD (0.74) | PIK3CDPIK3CGPIK3CBPIK3CACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140031355-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2014-01-30 | — | — | US | claimed |
| US-20140031355-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2014-01-30 | — | — | US | disclosed |
| US-20140031355-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2014-01-30 | — | — | US | disclosed |
| WO-2012061696-A1 | 5 -CYANO-4, 6 -DIAMINOPYRIMIDINE OR 6 -AMINOPURINE DERIVATIVES AS PI3K- DELTA INHIBITORS | AMGEN INC. (US) | 2012-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140031355-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, SSB, MALT1 | PIK3CD 1672/4885PIK3CG 2394/4885PIK3CB 1689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.